Boston Scientific CorporationBSXNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank62
3Y CAGR+9.9%
5Y CAGR+4.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+9.9%/yr
vs -3.7%/yr prior
5Y CAGR
+4.1%/yr
Recent acceleration
Acceleration
+13.6pp
Accelerating
Percentile
P62
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.34% |
| Q3 2025 | 1.46% |
| Q2 2025 | 7.45% |
| Q1 2025 | -0.93% |
| Q4 2024 | 3.20% |
| Q3 2024 | 8.02% |
| Q2 2024 | 6.01% |
| Q1 2024 | -1.09% |
| Q4 2023 | 11.03% |
| Q3 2023 | -8.27% |
| Q2 2023 | 11.44% |
| Q1 2023 | 4.47% |
| Q4 2022 | 4.03% |
| Q3 2022 | -4.03% |
| Q2 2022 | 9.91% |
| Q1 2022 | -8.07% |
| Q4 2021 | 8.16% |
| Q3 2021 | -4.91% |
| Q2 2021 | 10.01% |
| Q1 2021 | -0.78% |
| Q4 2020 | 4.37% |
| Q3 2020 | 23.31% |
| Q2 2020 | -18.40% |
| Q1 2020 | -10.44% |
| Q4 2019 | 7.91% |
| Q3 2019 | 4.55% |
| Q2 2019 | 11.39% |
| Q1 2019 | -8.14% |
| Q4 2018 | 8.99% |
| Q3 2018 | -2.58% |
| Q2 2018 | 4.58% |
| Q1 2018 | -3.40% |
| Q4 2017 | 10.66% |
| Q3 2017 | -1.85% |
| Q2 2017 | 2.65% |
| Q1 2017 | -4.47% |
| Q4 2016 | 7.81% |
| Q3 2016 | -1.41% |
| Q2 2016 | 8.80% |
| Q1 2016 | -7.85% |